NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis.
Published in Science translational medicine • Apr 13, 2016
Authors:,,
Hui Wang
Xiufei Liu
Min Long
Abstract
Cancer is a common comorbidity of diabetic patients; however, little is known about the effects that antidiabetic drugs have on tumors. We discovered that common classes of drugs used in type 2 diabetes mellitus, the hypoglycemic dipeptidyl peptidase-4 inhibitors (DPP-4i) saxagliptin and sitagliptin...
Finding related papers...
Discussions
(0)No comments yet
Be the first to share your thoughts!